CIBACALCIN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIBACALCIN is a small-molecule injectable approved in 1986 by Novartis. The specific indication and mechanism of action are not publicly documented in this dataset. This product represents a legacy therapeutic with decades of clinical use.
LOE Approaching
Product approaching loss of exclusivity with 30% competitive pressure indicates a defensive commercial posture focused on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CIBACALCIN offers limited growth opportunity as a legacy product in LOE phase; career development is best suited for commercial professionals seeking experience in mature portfolio management and generic transition strategy. Roles will focus on defending market share and operational efficiency rather than innovation.
Brand ManagerField Sales Representative
Worked on CIBACALCIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.